CUR Curidium Medica

 

TIDMAVCT TIDMCUR 
 
RNS Number : 2305O 
Avacta Group PLC 
03 March 2009 
 

Avacta Group plc 
 
 
("Avacta" or "the Company") 
 
 
Completion of Acquisition of Curidium Medica plc/Issue of Equity/ 
Board Changes/Director-PDMR Shareholding 
 
 
Avacta Group plc (AIM: AVCT.L) which develops innovative detection and analysis 
technology aimed primarily at the pharmaceutical and diagnostics markets, is 
pleased to announce that all of the conditions pursuant to the recommended offer 
for Curidium Medica plc (the "Acquisition") have been satisfied and the 
Acquisition has therefore been completed. 
 
 
Accordingly, application has been made for 274,679,825 new ordinary shares of 
0.1 pence each ("Ordinary Shares")  to be issued in connection with the 
Acquisition  and dealings are expected to commence at 8:00 am on Thursday 5 
March 2009.  In accordance with the Circular to shareholders, the new Ordinary 
Shares will be allotted on 4 March 2009. 
 
 
Further to the announcement made on 9 January 2009,  the Directors of Avacta are 
pleased to confirm that Dr Barry Porter (aged 51) has joined the board of the 
Company as a Non-Executive Director, with immediate effect.   Simon Webster, 
Kurt Baldwin and Russell Hodgetts have resigned as executive directors but 
remain as key employees of the Company and will sit on the newly created 
operating board. 
 
 
Following the issue of the new Ordinary Shares, the issued share capital of 
Avacta is 1,118,240,649, which figure may be used by shareholders as the 
denominator for the calculations by which they will determine if they are 
required to notify their interest in, or a change to their interest in, the 
Company under the FSA's Disclosure and Transparency Rules. 
 
 
The following information in respect of Dr Barry Porter is disclosed pursuant to 
Rule 17, Schedule Two, paragraph (g): 
 
 
Current Appointments: 
 
 
Union Life Sciences Ltd 
Curidium Medica plc 
InhibOx Ltd 
 
 
Past Appointments: 
 
 
ReOx Ltd 
De Novo Pharmaceuticals Ltd 
 
 
 
 
Save for the above, there is no further information to disclose. 
 
 
3 March 2009 
 
 
Enquiries: 
 
 
+---------------------------------------+---------------------------------------+ 
| Avacta Group plc                      | Tel: 0870 835 4367                    | 
| Alastair Smith, Chief Executive       |                                       | 
| Officer                               |                                       | 
| Tim Sykes, Chief Financial Officer    |                                       | 
| www.avacta.com                        |                                       | 
+---------------------------------------+---------------------------------------+ 
| Daniel Stewart & Company plc          | Tel: 020 7776 6550                    | 
| Lindsay Mair/Charlotte Stranner/Tessa |                                       | 
| Smith                                 |                                       | 
| www.danielstewart.co.uk               |                                       | 
+---------------------------------------+---------------------------------------+ 
| Novum Securities Limited              | Tel: 020 7562 4700                    | 
| Henry Turcan                          |                                       | 
+---------------------------------------+---------------------------------------+ 
| Haggie Financial LLP                  | Tel: 020 7417 8989                    | 
| Nicholas Nelson/Kathy Boate           | Nicholas.nelson@haggie.co.uk          | 
+---------------------------------------+---------------------------------------+ 
 
 
 
 
Notes to Editors: 
 
 
 
 
Avacta was spun-out from the University of Leeds in 2004 by its current 
management team as a biophysics company, with the aim of combining the 
disciplines of physics and biology to develop innovative technologies and expert 
technical services to address needs in the pharmaceutical, defence and clinical 
diagnostics markets. Avacta has a core bio-analytical technology development 
programme addressing the needs of the biopharmaceutical sector to fully 
characterise their new products at the earliest stage in their development to 
reduce the risk of late stage failure. High value solutions in clinical 
diagnostics are also being targeted for these core bio-analytical technologies 
and for Avacta's trace gas analysis technology as well as opportunities in 
industrial and military sensing applications. A successful and growing part of 
the Avacta business model is its technical services arm, Avacta Analytical 
Limited, which is focused on providing leading edge contract research to the 
biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed 
on AIM in August 2006 through the reverse takeover of Readybuy plc which changed 
its name to Avacta Group plc. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCILFLVVSIVIIA 
 

Curidium Medica (LSE:CUR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Curidium Medica (LSE:CUR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024